KRTL Biotech Advances Global Access to Women’s Health Pharmaceuticals Through Strategic Portfolio Expansion

KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company") today announced that its subsidiary, KRTL Biotech, Inc., is spotlighting its expanding women’s health pharmaceutical portfolio, which includes critical treatments supporting reproductive wellness, maternal care, and gynecological health.

The products, developed in collaboration with Industria Químico-Farmacéutica SIGMA Corp., represent one of the most socially impactful categories within the Company’s international pipeline. These therapeutics are widely used across Latin America in both clinical and over-the-counter settings and are now under evaluation for global export and U.S. regulatory pathways.

"Women’s health is foundational to community health," said Daniel Bishop, CEO of KRTL Biotech. "Our product line addresses real needs — from prenatal support to gynecological infections — using formats that meet international standards for safety, accessibility, and affordability."

Featured Women’s Health Products:

The portfolio includes prenatal supplements such as iron with folic acid and multivitamins, as well as gynecological treatments like clotrimazole (in both topical and vaginal formulations) and fluconazole. It also encompasses vaginal antiseptics, probiotics, and therapeutic products designed to support menstrual care and hormonal balance.

These formulations are actively distributed across Bolivia through public health channels, pharmacies, and hospital procurement. Several of these products are listed on national formularies and are already included in maternal and child health programs.

Together, these products empower caregivers, clinics, and women with options for preventive care, treatment of infections, and nutritional support during pregnancy.

"At SIGMA, we have long understood that advancing women’s health is not only a clinical goal but a social imperative," said Patricia Wilstermann, CEO of SIGMA. "We’re proud that these products serve both the public and private sectors in Bolivia — and we’re even more proud to bring this experience to a global platform with KRTL."

KRTL Biotech is currently exploring regulatory alignment for select women’s health products in the U.S. and other regions. Several supplements and topicals are eligible for classification under OTC Monograph frameworks, while prescription antifungals and prenatal complexes may qualify for ANDA submission or international export approvals.

"As we expand our women’s health footprint, we’re doing so with a clear commitment to equity, quality, and responsible commercialization," said Cesar Herrera, CEO of KRTL Holding Group Inc. "These products speak directly to unmet health needs worldwide — and we’re prepared to deliver."

About KRTL Holding Group, Inc.

KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.

About KRTL Biotech, Inc.

KRTL Biotech, Inc., a 51% majority-owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), recently completed a merger with Industria Químico-Farmacéutica SIGMA Corp. S.R.L., integrating SIGMA’s decades of pharmaceutical expertise and infrastructure into KRTL’s international life sciences platform. This merger combines KRTL’s research, compliance, and global market access with SIGMA’s advanced Bolivian manufacturing capabilities, aligning both companies to deliver world-class pharmaceutical and nutraceutical solutions.

About Industria Químico Farmacéutica SIGMA Corp SRL

SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.

For more information:

www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about

Forward-Looking Statements

This press release contains statements and information that, to the extent that they are not historical fact, may constitute  “forward-looking statements” within the meaning of applicable securities legislation. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments and acquisitions; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company. Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law.